Search icon
Learn, Analyse & Invest
only with
Orca logoArrow icon
+91
Download Orca
orca play storeorca apple store
To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Krebs Biochemicals & Industries Ltd.

Krebs Biochem.&Inds

0.00

0.00 (0.00)%

NSE

BSE

Subsidiaries

No Data Available

No Subsidiaries Data available

Management

1. Rakesh Kalbate
Company Secretary & Compliance Officer
2. R T Ravi
Chairman
3. Manish Jain
Managing Director & CEO
4. Pabitra Bhattacharya
Non Independent & Non Executive Director
5. Avinash Ravi
Non Independent & Non Executive Director
6. PM Kathariya
Non Executive Independent Director
7. Dipti Shah
Non Executive Independent Director
8. Satya Prakash Chigurupati
Non Executive Independent Director
9. Sumanth Karlapudi
Non Executive Independent Director

Contact Information

Company Address

Kothapalli Village, Anakapalli, Kasimkota Mandal
Vishakhapatnam, Andhra Pradesh - 531031
www.krebsbiochem.com
marketing@krebsbiochem.com / com_sec@krebsbiochem.com

Registrar

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: einward.ris@karvy.comWebsite: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001
Phone: 040 - 67162222/18003094001
Email: einward.ris@kfintech.com
Website: www.kfintech.com

Company Profile

Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade.

KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country.

KBIL’s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc.

The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc.

KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).

Product range of the company includes:

Bulk activities

Synthetic

  • Lavastatin
  • Simvastatin
  • I -Ephedrochiloride
  • l - Ephedrine Sulphate
  • l - Ephedrine Base (Liquid)
  • d - Pseudoephedrine Hydrochloride
  • d - Pseudoephedrine Sulphate
  • d - Pseudoephedrine Base
  • dl - Ephedrine Base
  • n - Methyl Ephedrine
  • d - Ephedrine Bitartarate
  • Vitamin C
  • Vitamin C (Coated)

Herbal

  • Calcium Sennosides - 20% & 60%
  • Garcinia Combogia Powdered Extract
  • Capsaicin - 50/100

Intermediates

  • Crude Lovastatin
  • Simvastatin Ammonium Salt

Products in pipeline

  • Pravastatin Sodium

Achievements/ recognition:

  • ISO 9002 in November 2001 
  • EDQM July 2003 
  • USFDA in November 2003 
  • ISO 9001 – 2000 in March 2004 
  • WHO GMP certification in November 2002 and renewed in March 2005
Enrich money logo